3. GOOD HEALTH AND WELL-BEING

Citigroup Inc. Sells 102,847 Shares of The Beauty Health Company (NASDAQ:SKIN)

Written by Amanda

Citigroup Inc. decreased its holdings in shares of The Beauty Health Company (NASDAQ:SKINFree Report) by 75.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,505 shares of the company’s stock after selling 102,847 shares during the period. Citigroup Inc.’s holdings in Beauty Health were worth $202,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Graham Capital Management L.P. bought a new position in shares of Beauty Health during the 3rd quarter worth approximately $1,057,000. GTS Securities LLC acquired a new stake in shares of Beauty Health in the 3rd quarter valued at $120,000. Tudor Investment Corp Et Al grew its holdings in shares of Beauty Health by 73.9% in the 3rd quarter. Tudor Investment Corp Et Al now owns 331,839 shares of the company’s stock worth $1,998,000 after purchasing an additional 140,967 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Beauty Health during the 3rd quarter worth about $88,000. Finally, AQR Capital Management LLC bought a new position in Beauty Health during the 3rd quarter valued at about $72,000. 93.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SKIN shares. TD Cowen raised their price objective on shares of Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a report on Wednesday, March 13th. Piper Sandler reissued an “underweight” rating and issued a $3.00 price objective (up previously from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th. DA Davidson restated a “buy” rating and set a $5.00 target price on shares of Beauty Health in a report on Friday, March 15th. Canaccord Genuity Group lifted their price target on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a report on Thursday, March 14th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $4.00 price objective (up previously from $3.00) on shares of Beauty Health in a report on Wednesday, March 13th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.50.

Read Our Latest Research Report on Beauty Health

Beauty Health Price Performance

Shares of SKIN stock opened at $4.44 on Friday. The firm has a market cap of $548.02 million, a price-to-earnings ratio of -5.77 and a beta of 0.94. The Beauty Health Company has a 12 month low of $1.35 and a 12 month high of $13.90. The company has a quick ratio of 5.28, a current ratio of 6.07 and a debt-to-equity ratio of 12.43. The stock has a 50-day moving average price of $3.37 and a 200 day moving average price of $3.75.

Beauty Health (NASDAQ:SKINGet Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. The company had revenue of $96.80 million during the quarter, compared to analysts’ expectations of $87.22 million. Beauty Health had a negative net margin of 25.65% and a negative return on equity of 18.85%. Beauty Health’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 EPS. Research analysts expect that The Beauty Health Company will post -0.12 EPS for the current year.

Beauty Health Profile

(Free Report)

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer’s preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

See Also

Institutional Ownership by Quarter for Beauty Health (NASDAQ:SKIN)



Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

Citigroup Inc. decreased its holdings in shares of The Beauty Health Company (NASDAQ:SKINFree Report) by 75.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,505 shares of the company’s stock after selling 102,847 shares during the period. Citigroup Inc.’s holdings in Beauty Health were worth $202,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Graham Capital Management L.P. bought a new position in shares of Beauty Health during the 3rd quarter worth approximately $1,057,000. GTS Securities LLC acquired a new stake in shares of Beauty Health in the 3rd quarter valued at $120,000. Tudor Investment Corp Et Al grew its holdings in shares of Beauty Health by 73.9% in the 3rd quarter. Tudor Investment Corp Et Al now owns 331,839 shares of the company’s stock worth $1,998,000 after purchasing an additional 140,967 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Beauty Health during the 3rd quarter worth about $88,000. Finally, AQR Capital Management LLC bought a new position in Beauty Health during the 3rd quarter valued at about $72,000. 93.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SKIN shares. TD Cowen raised their price objective on shares of Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a report on Wednesday, March 13th. Piper Sandler reissued an “underweight” rating and issued a $3.00 price objective (up previously from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th. DA Davidson restated a “buy” rating and set a $5.00 target price on shares of Beauty Health in a report on Friday, March 15th. Canaccord Genuity Group lifted their price target on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a report on Thursday, March 14th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $4.00 price objective (up previously from $3.00) on shares of Beauty Health in a report on Wednesday, March 13th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.50.

Read Our Latest Research Report on Beauty Health

Beauty Health Price Performance

Shares of SKIN stock opened at $4.44 on Friday. The firm has a market cap of $548.02 million, a price-to-earnings ratio of -5.77 and a beta of 0.94. The Beauty Health Company has a 12 month low of $1.35 and a 12 month high of $13.90. The company has a quick ratio of 5.28, a current ratio of 6.07 and a debt-to-equity ratio of 12.43. The stock has a 50-day moving average price of $3.37 and a 200 day moving average price of $3.75.

Beauty Health (NASDAQ:SKINGet Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. The company had revenue of $96.80 million during the quarter, compared to analysts’ expectations of $87.22 million. Beauty Health had a negative net margin of 25.65% and a negative return on equity of 18.85%. Beauty Health’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.03 EPS. Research analysts expect that The Beauty Health Company will post -0.12 EPS for the current year.

Beauty Health Profile

(Free Report)

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer’s preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

See Also

Institutional Ownership by Quarter for Beauty Health (NASDAQ:SKIN)



Receive News & Ratings for Beauty Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Beauty Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment